Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$225.18 USD

225.18
487,798

+3.33 (1.50%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $225.18 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Bruker (BRKR) Stock Rises on Strong Preliminary Q4 Show

Bruker's (BRKR) revenue growth is expected to beat expectations for the fourth quarter and 2019.

Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up

Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.

STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View

STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates

Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.

IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y

The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.

CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4

CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.

Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong

We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.

Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates

Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.

Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand

Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.

Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid

We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.

AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss

AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Align Technology (ALGN) Earnings Beat in Q4, Margins Rise

We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.

Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates

Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates

PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line

Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.

DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Add STERIS (STE) to Portfolio Now

Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.

NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?

NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Steris (STE) Up 4.5% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.

Steris (STE) Surpasses Q2 Earnings and Revenue Estimates

Steris (STE) delivered earnings and revenue surprises of 4.76% and 2.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.